Riesgo de recurrencia en cáncer diferenciado de tiroides: escala MINSAL

Background: Differentiated thyroid cancer (DTC) is generally associated with a favorable prognosis. Its treatment requires surgery, selective use of radioiodine and levothyroxine, and its intensity must be adjusted to the initial risks of mortality and recurrence. Aim: To validate the risk of recurrence classification developed by the Chilean Ministry of Health in 2013 (MINSAL 2013), and compare it with the American Thyroid Association (ATA) 2009 and 2015 classifications. Material and Methods: Retrospective study of 362 patients with DTC aged 44.3 ± 13.4 years (84% women), treated with total thyroidectomy, selective radioiodine ablation and levothyroxine and followed for a median of 4.2 years (range 2.0-7.8). Risk of recurrence was estimated with MINSAL 2013, ATA 2009 and ATA 2015 classifications, and risk of mortality with 7th and 8th American Joint Committee on Cancer (AJCC)/TNM systems. Clinical data obtained during follow-up were used to detect structural and biochemical persistence/recurrence. Results: A mean dose of 104 ± 48 mCi radioiodine was received by 91% of patients. MINSAL 2013 classified 148 (41%), 144 (40%), 67 (19%) and 3 (1%) patients as very low, low, intermediate and high risk of recurrence, respectively. Forty-five (12.4%) patients had persistence or recurrence during follow-up: 33 structural and 12 biochemical. Rates of persistence/recurrence on each category of MINSAL 2013 were 4.1%, 7.6%, 37.3% and 100%, respectively (p < 0.01). Areas under Receiver Operating Characteristic curves for persistence or recurrence of MINSAL 2013, ATA 2009 and ATA 2015 were 0.77 vs 0.73 vs 0.72, respectively. Conclusions: MINSAL 2013 classifies appropriately DTC patients and estimates correctly their risk of persistence or recurrence.

Saved in:
Bibliographic Details
Main Authors: Domínguez,José Miguel, Martínez,María Teresa, Massardo,José Miguel, Muñoz,Suelí, Droppelmann,Nicolás, González,Hernán E., Mosso,Lorena
Format: Digital revista
Language:Spanish / Castilian
Published: Sociedad Médica de Santiago 2018
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000300282
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0034-98872018000300282
record_format ojs
spelling oai:scielo:S0034-988720180003002822018-06-20Riesgo de recurrencia en cáncer diferenciado de tiroides: escala MINSALDomínguez,José MiguelMartínez,María TeresaMassardo,José MiguelMuñoz,SuelíDroppelmann,NicolásGonzález,Hernán E.Mosso,Lorena Thyroid Neoplasms Neoplasm Recurrence Local Predictive Value of Tests Treatment Outcome Background: Differentiated thyroid cancer (DTC) is generally associated with a favorable prognosis. Its treatment requires surgery, selective use of radioiodine and levothyroxine, and its intensity must be adjusted to the initial risks of mortality and recurrence. Aim: To validate the risk of recurrence classification developed by the Chilean Ministry of Health in 2013 (MINSAL 2013), and compare it with the American Thyroid Association (ATA) 2009 and 2015 classifications. Material and Methods: Retrospective study of 362 patients with DTC aged 44.3 ± 13.4 years (84% women), treated with total thyroidectomy, selective radioiodine ablation and levothyroxine and followed for a median of 4.2 years (range 2.0-7.8). Risk of recurrence was estimated with MINSAL 2013, ATA 2009 and ATA 2015 classifications, and risk of mortality with 7th and 8th American Joint Committee on Cancer (AJCC)/TNM systems. Clinical data obtained during follow-up were used to detect structural and biochemical persistence/recurrence. Results: A mean dose of 104 ± 48 mCi radioiodine was received by 91% of patients. MINSAL 2013 classified 148 (41%), 144 (40%), 67 (19%) and 3 (1%) patients as very low, low, intermediate and high risk of recurrence, respectively. Forty-five (12.4%) patients had persistence or recurrence during follow-up: 33 structural and 12 biochemical. Rates of persistence/recurrence on each category of MINSAL 2013 were 4.1%, 7.6%, 37.3% and 100%, respectively (p < 0.01). Areas under Receiver Operating Characteristic curves for persistence or recurrence of MINSAL 2013, ATA 2009 and ATA 2015 were 0.77 vs 0.73 vs 0.72, respectively. Conclusions: MINSAL 2013 classifies appropriately DTC patients and estimates correctly their risk of persistence or recurrence.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.146 n.3 20182018-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000300282es10.4067/s0034-98872018000300282
institution SCIELO
collection OJS
country Chile
countrycode CL
component Revista
access En linea
databasecode rev-scielo-cl
tag revista
region America del Sur
libraryname SciELO
language Spanish / Castilian
format Digital
author Domínguez,José Miguel
Martínez,María Teresa
Massardo,José Miguel
Muñoz,Suelí
Droppelmann,Nicolás
González,Hernán E.
Mosso,Lorena
spellingShingle Domínguez,José Miguel
Martínez,María Teresa
Massardo,José Miguel
Muñoz,Suelí
Droppelmann,Nicolás
González,Hernán E.
Mosso,Lorena
Riesgo de recurrencia en cáncer diferenciado de tiroides: escala MINSAL
author_facet Domínguez,José Miguel
Martínez,María Teresa
Massardo,José Miguel
Muñoz,Suelí
Droppelmann,Nicolás
González,Hernán E.
Mosso,Lorena
author_sort Domínguez,José Miguel
title Riesgo de recurrencia en cáncer diferenciado de tiroides: escala MINSAL
title_short Riesgo de recurrencia en cáncer diferenciado de tiroides: escala MINSAL
title_full Riesgo de recurrencia en cáncer diferenciado de tiroides: escala MINSAL
title_fullStr Riesgo de recurrencia en cáncer diferenciado de tiroides: escala MINSAL
title_full_unstemmed Riesgo de recurrencia en cáncer diferenciado de tiroides: escala MINSAL
title_sort riesgo de recurrencia en cáncer diferenciado de tiroides: escala minsal
description Background: Differentiated thyroid cancer (DTC) is generally associated with a favorable prognosis. Its treatment requires surgery, selective use of radioiodine and levothyroxine, and its intensity must be adjusted to the initial risks of mortality and recurrence. Aim: To validate the risk of recurrence classification developed by the Chilean Ministry of Health in 2013 (MINSAL 2013), and compare it with the American Thyroid Association (ATA) 2009 and 2015 classifications. Material and Methods: Retrospective study of 362 patients with DTC aged 44.3 ± 13.4 years (84% women), treated with total thyroidectomy, selective radioiodine ablation and levothyroxine and followed for a median of 4.2 years (range 2.0-7.8). Risk of recurrence was estimated with MINSAL 2013, ATA 2009 and ATA 2015 classifications, and risk of mortality with 7th and 8th American Joint Committee on Cancer (AJCC)/TNM systems. Clinical data obtained during follow-up were used to detect structural and biochemical persistence/recurrence. Results: A mean dose of 104 ± 48 mCi radioiodine was received by 91% of patients. MINSAL 2013 classified 148 (41%), 144 (40%), 67 (19%) and 3 (1%) patients as very low, low, intermediate and high risk of recurrence, respectively. Forty-five (12.4%) patients had persistence or recurrence during follow-up: 33 structural and 12 biochemical. Rates of persistence/recurrence on each category of MINSAL 2013 were 4.1%, 7.6%, 37.3% and 100%, respectively (p < 0.01). Areas under Receiver Operating Characteristic curves for persistence or recurrence of MINSAL 2013, ATA 2009 and ATA 2015 were 0.77 vs 0.73 vs 0.72, respectively. Conclusions: MINSAL 2013 classifies appropriately DTC patients and estimates correctly their risk of persistence or recurrence.
publisher Sociedad Médica de Santiago
publishDate 2018
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000300282
work_keys_str_mv AT dominguezjosemiguel riesgoderecurrenciaencancerdiferenciadodetiroidesescalaminsal
AT martinezmariateresa riesgoderecurrenciaencancerdiferenciadodetiroidesescalaminsal
AT massardojosemiguel riesgoderecurrenciaencancerdiferenciadodetiroidesescalaminsal
AT munozsueli riesgoderecurrenciaencancerdiferenciadodetiroidesescalaminsal
AT droppelmannnicolas riesgoderecurrenciaencancerdiferenciadodetiroidesescalaminsal
AT gonzalezhernane riesgoderecurrenciaencancerdiferenciadodetiroidesescalaminsal
AT mossolorena riesgoderecurrenciaencancerdiferenciadodetiroidesescalaminsal
_version_ 1755988579615506432